Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jan;236(1):417-426.
doi: 10.1002/jcp.29870. Epub 2020 Jun 22.

Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial

Helda Tutunchi  1   2 , Alireza Ostadrahimi  2 , Maryam Saghafi-Asl  2 , Neda Roshanravan  3 , Abolhassan Shakeri-Bavil  4 , Mohammad Asghari-Jafarabadi  5 , Nazila Farrin  6 , Majid Mobasseri  7
Affiliations
Randomized Controlled Trial

Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial

Helda Tutunchi et al. J Cell Physiol. 2021 Jan.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common noncommunicable diseases worldwide. The present study aimed to investigate the effects of oleoylethanolamide (OEA) supplementation combined with calorie restriction on inflammation, body composition, and hepatic fibrosis among obese patients with NAFLD. In this 12-week randomized clinical trial, 76 obese patients newly diagnosed with NAFLD were randomly allocated into either OEA or placebo group. The weight-loss diet was also designed for both groups. Pre- and postintervention messenger RNA expression levels of the transcription factor nuclear factor-κB (NF-κB), interleukin-6 (IL-6) and IL-10, body composition, and NAFLD fibrosis score were assessed. At the end of the study, the OEA group showed lower NF-κB and IL-6 expression levels compared to the placebo (p < .01). However, IL-10 expression level was approximately twofold higher in the OEA group compared to the placebo group (p = .008). A significant reduction was observed in the fat mass of the OEA group compared to the placebo (p = .044) postintervention. In addition, OEA supplementation led to a significant increase in fat-free mass in the OEA group compared to the placebo (p = .032). A remarkable increase was observed in resting metabolic rate (RMR) in the OEA group (p = .009); however, it was not found in the placebo group. There were no significant between-group differences in RMR postintervention. In addition, no significant within-and between-group differences were observed in the NAFLD fibrosis score at the end of the trial. Treatment with OEA along with weight-loss intervention could significantly improve inflammation and body composition in patients with NAFLD.

Keywords: body composition; interleukin-10; interleukin-6; nonalcoholic fatty liver disease; nuclear factor-κB; oleoylethanolamide.

PubMed Disclaimer

References

REFERENCES

    1. de Alwis, N. M., & Day, C. P. (2008). Non-alcoholic fatty liver disease: The mist gradually clears. Journal of Hepatology, 48(Suppl. 1), S104-S112. https://doi.org/10.1016/j.jhep.2008.01.009
    1. Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., … Day, C. P. (2007). The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 45(4), 846-854. https://doi.org/10.1002/hep.21496
    1. Anton, M., Alen, F., Gomez de Heras, R., Serrano, A., Pavon, F. J., Leza, J. C., … Orio, L. (2017). Oleoylethanolamide prevents neuroimmune HMGB1/TLR4/NF-κB danger signaling in rat frontal cortex and depressive-like behavior induced by ethanol binge administration. Addiction Biology, 22(3), 724-741. https://doi.org/10.1111/adb.12365
    1. Asrih, M., & Jornayvaz, F. R. (2013). Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. Journal of Endocrinology, 218(3), R25-R36. https://doi.org/10.1530/joe-13-0201
    1. den Boer, M. A., Voshol, P. J., Schroder-van der Elst, J. P., Korsheninnikova, E., Ouwens, D. M., Kuipers, F., … Romijn, J. A. (2006). Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology, 147(10), 4553-4558. https://doi.org/10.1210/en.2006-0417

Publication types

LinkOut - more resources